Alzheimer's disease (AD) continues to remain a public health concern especially for seniors globally. Increased life expectancy owing to improvement in medical advances may have increased AD's prevalence. It remains a matter of concern for stakeholders to look at progress made over the years and to fill the numerous gaps targeted at preventing the onset of AD and/or treating existing condition. In recent times, funding for AD research has increased in the United States (U.S) but the economic burden isn't left out. Controversies on gene modification still exist. The search for a definitive treatment still continues since recently approved drug-Aducanumab still has uncertainty concerning safety and efficacy. Newer therapies hold promise but we are still uncertain as we await their approval and real world evidence for safety and efficacy.